The Role of miR-375-3p and miR-200b-3p in Gastrointestinal Stromal Tumors.
3' Untranslated Regions
Apoptosis
/ genetics
Cell Line, Tumor
Cell Movement
/ genetics
Cell Proliferation
/ genetics
Cell Survival
/ genetics
DNA-Binding Proteins
/ metabolism
Down-Regulation
ErbB Receptors
/ genetics
Gastrointestinal Neoplasms
/ genetics
Gastrointestinal Stromal Tumors
/ genetics
Gene Expression Regulation, Neoplastic
/ genetics
Humans
MicroRNAs
/ genetics
Transcription Factors
/ metabolism
GIST
gastrointestinal stromal tumor
miR-200b-3p
miR-375-3p
miRNA
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
21 Jul 2020
21 Jul 2020
Historique:
received:
11
06
2020
revised:
10
07
2020
accepted:
17
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
5
3
2021
Statut:
epublish
Résumé
Deregulated microRNA (miRNA) expression profiles and their contribution to carcinogenesis have been observed in virtually all types of human cancer. However, their role in the pathogenesis of rare mesenchymal gastrointestinal stromal tumors (GISTs) is not well defined, yet. In this study, we aimed to investigate the role of two miRNAs strongly downregulated in GIST-miR-375-3p and miR-200b-3p-in the pathogenesis of GIST. To achieve this, miRNA mimics were transfected into GIST-T1 cells and changes in the potential target gene mRNA and protein expression, as well as alterations in cell viability, migration, apoptotic cell counts and direct miRNA-target interaction, were evaluated. Results revealed that overexpression of miR-375-3p downregulated the expression of KIT mRNA and protein by direct binding to KIT 3'UTR, reduced GIST cell viability and migration rates. MiR-200b-3p lowered expression of ETV1 protein, directly targeted and lowered expression of EGFR mRNA and protein, and negatively affected cell migration rates. To conclude, the present study identified that miR-375-3p and miR-200b-3p have a tumor-suppressive role in GIST.
Identifiants
pubmed: 32708220
pii: ijms21145151
doi: 10.3390/ijms21145151
pmc: PMC7404198
pii:
doi:
Substances chimiques
3' Untranslated Regions
0
DNA-Binding Proteins
0
ETV1 protein, human
0
MIRN200 microRNA, human
0
MIRN375 microRNA, human
0
MicroRNAs
0
Transcription Factors
0
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Research Council of Lithuania
ID : MIP-006/2014
Références
Nature. 2010 Oct 14;467(7317):849-53
pubmed: 20927104
Mol Aspects Med. 2019 Dec;70:57-71
pubmed: 31558294
Cancer Immunol Immunother. 2014 Jul;63(7):699-711
pubmed: 24718681
Am J Transl Res. 2016 Mar 15;8(3):1551-9
pubmed: 27186281
Blood. 2000 Aug 1;96(3):925-32
pubmed: 10910906
PLoS One. 2015 Jul 14;10(7):e0132327
pubmed: 26172537
Oncogene. 2007 Nov 29;26(54):7560-8
pubmed: 17546049
Nature. 2012 Feb 15;482(7385):347-55
pubmed: 22337054
Cell Res. 2010 Jul;20(7):784-93
pubmed: 20548334
Clin Epigenetics. 2018 Apr 23;10:59
pubmed: 29713393
Mol Oncol. 2018 Jan;12(1):3-20
pubmed: 29124875
Appl Immunohistochem Mol Morphol. 2008 Jul;16(4):310-5
pubmed: 18528288
Virchows Arch. 2010 Feb;456(2):111-27
pubmed: 20165865
Int J Cancer. 2014 Sep 1;135(5):1011-8
pubmed: 24166096
Oncol Lett. 2018 Sep;16(3):3319-3326
pubmed: 30127930
Mol Med Rep. 2018 Sep;18(3):2571-2580
pubmed: 30015876
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818806499
pubmed: 30355273
EBioMedicine. 2019 Jun;44:439-451
pubmed: 31130475
Lab Invest. 2002 May;82(5):663-5
pubmed: 12004007
Oncogene. 2004 May 13;23(22):3999-4006
pubmed: 15007386
Mol Oncol. 2015 Aug;9(7):1421-33
pubmed: 25898773
Nat Protoc. 2010 May;5(5):929-34
pubmed: 20431538
Biosci Biotechnol Biochem. 2019 Jul;83(7):1289-1299
pubmed: 30999814
Clin Exp Pharmacol Physiol. 2019 Feb;46(2):144-152
pubmed: 30353914
Appl Immunohistochem Mol Morphol. 2019 Jan;27(1):54-58
pubmed: 28777148
Cancer Res. 2017 Aug 1;77(15):4051-4064
pubmed: 28619708
Oncotarget. 2017 Mar 8;8(36):60589-60604
pubmed: 28947997
EBioMedicine. 2016 Oct;12:34-42
pubmed: 27720213
Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12843-8
pubmed: 16908864
Oncotarget. 2015 Feb 10;6(4):1954-66
pubmed: 25557174
Adv Anat Pathol. 2017 Sep;24(5):259-267
pubmed: 28632504
Int J Mol Sci. 2018 Jan 30;19(2):
pubmed: 29385688
Nat Rev Cancer. 2011 Nov 17;11(12):865-78
pubmed: 22089421
J Gastroenterol. 2008;43(7):499-508
pubmed: 18648736
World J Gastroenterol. 2018 Aug 14;24(30):3313-3329
pubmed: 30122873
Nat Rev Cancer. 2015 Jun;15(6):321-33
pubmed: 25998712
Int J Mol Sci. 2020 Jan 29;21(3):
pubmed: 32013265
Biomed Pharmacother. 2018 Oct;106:1135-1143
pubmed: 30119180
World J Gastroenterol. 2012 May 28;18(20):2569-75
pubmed: 22654456
Anticancer Res. 2003 May-Jun;23(3B):2253-60
pubmed: 12894500
Tumour Biol. 2016 Jan;37(1):463-71
pubmed: 26224477
Oncotarget. 2017 Jun 6;8(23):37225-37238
pubmed: 28402935
Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819892590
pubmed: 31795847
Oncotarget. 2017 Jul 12;8(49):85276-85289
pubmed: 29156719
Elife. 2015 Aug 12;4:
pubmed: 26267216